Consensus RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.1 ^USD	+3.85%		+1.89%	-67.40%

Apr. 09	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	CI
Mar. 27	JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	MT

Evolution of the average Target Price on RAPT Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

47d858a6ff5846709.kEVgg7pvgMj3hrKZ_fYfPG9Rjgq_p0wx6wLmtWyonh8.0T0I4os_uKSPt97OzbErVy0hvjz1lH8C2TW17SqRpybSDS_P9wm5mJru2Q~67a47d784b4739864e256c387a67455b

Analyst Recommendations on RAPT Therapeutics, Inc.

JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	Mar. 27	MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61	Feb. 22	MT
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating	Feb. 21	MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10	Feb. 21	MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy	Feb. 21	MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15	Feb. 21	MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating	Feb. 20	MT
Piper Sandler Cuts RAPT Therapeutics' Price Target to $18 From $31, Keeps Overweight Rating	Feb. 20	MT
Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral From Overweight	Feb. 20	MT
Evercore ISI Starts Coverage on RAPT Therapeutics With Outperform Rating	Feb. 16	MT
Wolfe Research Starts RAPT Therapeutics With Outperform Rating, $39 Price Target	Feb. 15	MT
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC	Nov. 03	CI
Berenberg Initiates RAPT Therapeutics With Buy Rating, Price Target is $34	23-09-14	MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $32 From $39, Maintains Overweight Rating	23-08-16	MT
Piper Sandler Adjusts Price Target on RAPT Therapeutics to $31 From $28, Maintains Overweight Rating	23-08-14	MT
Stifel Initiates Coverage on RAPT Therapeutics with Buy Rating, $40 Price Target	23-08-09	MT
Barclays Initiates RAPT Therapeutics With Overweight Rating, $35 Price Target	23-06-15	MT
HC Wainwright Adjusts Price Target on RAPT Therapeutics to $41 From $43, Keeps Buy Rating	23-05-12	MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $42 From $48, Maintains Overweight Rating	23-03-21	MT
Guggenheim Lowers Price Target on RAPT Therapeutics to $48 From $55, Maintains Buy Rating	23-03-15	MT
HC Wainwright Adjusts Price Target on RAPT Therapeutics to $43 From $50, Maintains Buy Rating	23-03-15	MT
Cantor Fitzgerald Adjusts RAPT Therapeutics Price Target to $40 From $44, Maintains Overweight Rating	23-03-14	MT
Wells Fargo Adjusts Price Target on RAPT Therapeutics to $48 From $55, Maintains Overweight Rating	23-01-04	MT
Guggenheim Starts RAPT Therapeutics at Buy With $55 Price Target	23-01-04	MT
Goldman Sachs Initiates RAPT Therapeutics at Buy With $27 Price Target	22-12-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.1 USD

Average target price

22 USD

Spread / Average Target

+171.60%

High Price Target

48 USD

Spread / Highest target

+492.59%

Low Price Target

10 USD

Spread / Lowest Target

+23.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering RAPT Therapeutics, Inc.

JPMorgan Chase
UBS
Barclays
Leerink Partners
HC Wainwright
Stifel Nicolaus
Piper Sandler
Cantor Fitzgerald
Evercore ISI
Wolfe Research
Berenberg Bank
Guggenheim
Wells Fargo Securities
Goldman Sachs
Capital One Securities
SVB Securities LLC
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar